• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.

作者信息

De Pas Tommaso, Spitaleri Gianluca, Pelosi Giuseppe, De Carlis Luciano, Lorizzo Katia, Locatelli Marzia, Curigliano Giuseppe, Toffalorio Francesca, Catania Chiara, de Braud Filippo

出版信息

J Thorac Oncol. 2009 Jan;4(1):138-9. doi: 10.1097/JTO.0b013e31819151e5.

DOI:10.1097/JTO.0b013e31819151e5
PMID:19096323
Abstract
摘要

相似文献

1
Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.厄洛替尼联合环孢素用于一名表皮生长因子受体突变的非小细胞肺癌肝移植受者的治疗
J Thorac Oncol. 2009 Jan;4(1):138-9. doi: 10.1097/JTO.0b013e31819151e5.
2
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.表皮生长因子受体酪氨酸激酶抑制剂在携带罕见表皮生长因子受体突变的非小细胞肺癌患者中的活性。
J Thorac Oncol. 2011 Nov;6(11):1895-901. doi: 10.1097/JTO.0b013e318227e8c6.
3
Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations.在无反应风险的情况下克服耐药性：阿法替尼和帕尼单抗在两例表皮生长因子受体突变且伴有T790M突变的非小细胞肺癌中的应用
Clin Lung Cancer. 2015 Sep;16(5):e97-9. doi: 10.1016/j.cllc.2015.02.005. Epub 2015 Mar 5.
4
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.培美曲塞联合厄洛替尼间断治疗表皮生长因子受体突变状态明确的经治晚期非鳞非小细胞肺癌的 II 期研究
Lung Cancer. 2013 Nov;82(2):271-5. doi: 10.1016/j.lungcan.2013.07.022. Epub 2013 Aug 6.
5
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.表皮生长因子受体突变阳性复发性非小细胞肺癌患者在严重皮肤毒性后对低剂量厄洛替尼的显著反应。
J Thorac Oncol. 2009 Dec;4(12):1585-6. doi: 10.1097/JTO.0b013e3181bbb2b9.
6
Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
J Thorac Oncol. 2009 Jul;4(7):936-7. doi: 10.1097/JTO.0b013e3181a9a0a2.
7
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.表皮生长因子受体 - 酪氨酸激酶抑制剂（EGFR-TKI）联合贝伐单抗用于表皮生长因子受体（EGFR）突变的非小细胞肺癌的再挑战治疗
Cancer Chemother Pharmacol. 2015 Oct;76(4):835-41. doi: 10.1007/s00280-015-2867-8. Epub 2015 Sep 8.
8
Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.两代患有晚期肺腺癌且对厄洛替尼有持久反应的从不吸烟者。
J Thorac Oncol. 2012 Jul;7(7):1200-1. doi: 10.1097/JTO.0b013e318250ed89.
9
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.厄洛替尼单药或联合贝伐珠单抗作为 EGFR 突变的晚期非鳞状非小细胞肺癌患者的一线治疗（JO25567）：一项开放标签、随机、多中心、Ⅱ期研究。
Lancet Oncol. 2014 Oct;15(11):1236-44. doi: 10.1016/S1470-2045(14)70381-X. Epub 2014 Aug 27.
10
First case of A859T epidermal growth factor receptor mutation responding to erlotinib.首例对厄洛替尼有反应的A859T表皮生长因子受体突变病例。
J Thorac Oncol. 2011 Mar;6(3):639-40. doi: 10.1097/JTO.0b013e3182037c0c.

引用本文的文献

1
PPP3CB overexpression mediates EGFR TKI resistance in lung tumors via calcineurin/MEK/ERK signaling.PPP3CB 过表达通过钙调神经磷酸酶/MEK/ERK 信号通路介导肺肿瘤对 EGFR TKI 的耐药性。
Life Sci Alliance. 2024 Oct 1;7(12). doi: 10.26508/lsa.202402873. Print 2024 Dec.
2
Current Status of Malignant Tumors after Organ Transplantation.器官移植后恶性肿瘤的现状。
Biomed Res Int. 2022 Feb 18;2022:5852451. doi: 10.1155/2022/5852451. eCollection 2022.